GlaxoSmithKline, Drug Prices & Medicare Spending

GlaxoSmithKline manufactures 16 drugs tracked by Medicare Part D with total spending of $9.3B.

Drugs Tracked

$9.3B

Medicare Spending

$125.77

Avg Cost/Claim

94%

Have Generics

GlaxoSmithKline Drugs, Ranked by Medicare Spending

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Trelegy Ellipta	Fluticasone/Umeclidinium/Vilanterol	$380.00	$2.9B	+19.8%	No
2	Nucala	Mepolizumab	$2,720.00	$1.5B	+12.4%	Yes
3	Breo Ellipta	Fluticasone/Vilanterol	$221.00	$1.2B	-4.3%	Yes
4	Benlysta	Belimumab	$4,710.00	$876.0M	+14.6%	Yes
5	Advair Diskus	Fluticasone/Salmeterol	$159.00	$678.0M	-18.9%	Yes
6	Anoro Ellipta	Umeclidinium/Vilanterol	$229.00	$567.0M	+4.2%	Yes
7	Incruse Ellipta	Umeclidinium	$185.00	$345.0M	-2.4%	Yes
8	Flolan	Epoprostenol	$19,167.00	$345.0M	-4.8%	Yes
9	Bupropion	Bupropion Hydrochloride	$12.00	$178.0M	-22.4%	Yes
10	Lamotrigine	Lamotrigine	$17.00	$145.0M	-22.4%	Yes
11	Carvedilol	Carvedilol	$11.00	$123.0M	-24.6%	Yes
12	Paroxetine	Paroxetine Hydrochloride	$18.00	$89.0M	-22.4%	Yes
13	Sumatriptan	Sumatriptan	$18.00	$89.0M	-22.4%	Yes
14	Ropinirole	Ropinirole Hydrochloride	$48.00	$89.0M	-22.6%	Yes
15	Valacyclovir	Valacyclovir	$18.00	$89.0M	-12.4%	Yes
16	Lovaza	Omega-3-Acid Ethyl Esters	$143.00	$89.0M	-34.2%	Yes

Frequently Asked Questions

GlaxoSmithKline manufactures 16 drugs tracked by Medicare Part D, with total annual spending of $9.3B.

Flolan (Epoprostenol) is the most expensive at $19,167.00 per claim.

15 of 16 GlaxoSmithKline drugs (94%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.

this entity is one of the data points covered by this site’s U.S. Medicare prescription-drug pricing dataset. The detail above comes directly from CMS Medicare Part D Drug Spending data; the context that follows situates the headline numbers against the broader distribution across U.S. prescription drugs.

The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. prescription drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.

Source: CMS Medicare Part D Spending, 2026.